$RVMD just recorded a 25-point drop in its ACCE composite score, falling from 46 to 21 out of 100. That is a large single move. A shift of that magnitude typically reflects deterioration across more than one subscore — growth, value, quality, and momentum are the four pillars that feed the composite — rather than noise in a single factor.
The stock currently trades at $155.31 with a market cap of $33.16B. The forward P/E sits at -27.7, which signals the company is not yet profitable on a forward earnings basis. That negative earnings figure matters because it directly pressures the value and quality subscores. A company burning cash with no near-term earnings visibility scores poorly on both dimensions almost by definition.
The analyst consensus target is $186.33, which sits above the current price. That gap suggests sell-side analysts still see upside from here, but the ACCE model weighs a broader set of quantitative signals than analyst targets alone.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
What it means
A score of 21 places $RVMD firmly in cautious territory on the ACCE scale. Here is what likely drove a drop this size:
Momentum pressure. A sharp price move — either a run-up that stretched valuation or a selloff that broke trend signals — can hit the momentum subscore hard. Either direction can trigger a reset depending on how the model reads near-term price behavior relative to benchmarks.
Value compression. With a forward P/E of -27.7, there are no positive earnings to anchor a traditional value score. If revenue growth expectations softened or the market re-rated the stock's risk premium, the value subscore would follow.
Quality signals. Pre-profitability biotech and pharma names like $RVMD carry inherent quality score headwinds. Cash burn rate, balance sheet leverage, and return metrics all feed this subscore. Any deterioration in those underlying figures — or a shift in how the model weights them — can move the needle quickly.
Growth re-rating. Clinical-stage healthcare companies live and die by pipeline progress. If forward growth estimates were revised down, or if a comparable peer re-priced the sector, the growth subscore would compress alongside it.
None of this means the underlying business has collapsed. The analyst target of $186.33 versus a current price of $155.31 shows the street still sees a path higher. But the ACCE score reflects quantitative signals right now, and right now those signals are weak.
For the full breakdown of $RVMD's individual subscores and updated data, see the live stock page at acceinvestments.com/stocks/RVMD.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
